Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

HIV prevalence

Number of new HIV diagnoses in gay men falls for first time

New diagnoses of HIV in England have fallen among men who have sex with men, with the greatest decline seen in a handful of clinics in London, according to figures from Public Health England (PHE) and contained in a new report ‘Fall in new HIV diagnoses among MSM at selected London sexual health clinics’, (online, 23 June 2017).

It is the first time a drop in the number of diagnoses has been seen, and has been confirmed by a special analysis of the data after some sexual health clinics reported in the media that they had noticed a decrease.

PHE found a fall of 17% in new HIV diagnoses in gay, bisexual and other men who have sex with men from 2,060 in 2014–2015 to 1,700 in 2015–2016.

In London, there was a drop of 32% (from 880 to 595) at five major London clinics, and an 8% fall (833 to 792) at 30 other London clinics.

PHE said national guidelines in place since 2012 recommending three-monthly testing for those at highest risk, had contributed to the fall in diagnoses.

They said that among the five clinics in London that saw the steepest decline, the number of HIV tests carried out between 2013 and 2016 had increased by 50%.

Further analysis showed that repeat tests had increased by 60%.

Treatment guidelines that indicate early treatment with ART to prevent onward transmission have also played a part, with men receiving treatment sooner after diagnosis on average at the clinics with the greatest fall in new diagnoses, the figures show.

The London clinics that had seen a particularly large fall in new diagnoses were taking part in the PROUD study of pre-exposure prophylaxis (PrEP).

Dr Michael Brady, medical director of the Terrence Higgins Trust, called the sharp drop in England “remarkable”.

“This points towards what can be achieved when we utilise all the weapons in our arsenal against HIV transmission,” he said.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203066

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • antiretroviral prep pill hiv ss 17

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.